Compare ProShares UltraShort Bloomberg Natural Gas ETF (KOLD) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares UltraShort Bloomberg Natural Gas ETF vs Recursion Pharmaceuticals Inc — how do they compare? ProShares UltraShort Bloomberg Natural Gas ETF trades at $24.75 (market cap $141.25M), while Recursion Pharmaceuticals Inc trades at $4.36 (market cap $2.14B). The key difference: Recursion Pharmaceuticals Inc is far larger — about 15.2× ProShares UltraShort Bloomberg Natural Gas ETF's market cap, and Recursion Pharmaceuticals Inc is more actively traded (30,789,535 versus 5,492,367). Which is the better fit depends on your goals — on Pluang, investors hold ProShares UltraShort Bloomberg Natural Gas ETF for 10 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| KOLD | RXRX | |
|---|---|---|
Market Cap | $141.25M | $2.14B |
Volume | 5,492,367 | 30,789,535 |
Sector | Leveraged / Inverse | Health |
52-Week High | $49.39 | $6.79 |
52-Week Low | $13.58 | $2.84 |
Typical Hold Time | 10 Days | 23 Days |
Enterprise Value | — | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KOLD is trading at $25.68, up 3.38% today, but faces bearish technical signals with 15 sell indicators versus 2 buy signals. The stock is trading near its pivot point of $25 with immediate resistance at $26 and support at $25. Recent news highlights volatility in natural gas markets with record production levels and geopolitical tensions affecting energy sector sentiment.
The outlook remains cautious with strong bearish momentum indicators and fundamental data gaps. Investment opportunity exists for contrarian traders near support levels, but risks include energy price volatility and production oversupply concerns. Technical weakness suggests potential for further downside testing of $24-$25 support zone.
Recursion Pharmaceuticals (RXRX) trades at $3.95, down 7.49% today, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported Q2 2026 earnings miss after two consecutive beats, while maintaining negative profitability metrics with a -961.97% net income margin. Recent strategic partnerships with Tempus and Roche aim to expand the AI-driven drug discovery pipeline through 2028.
RXRX presents high-risk growth potential with strong analyst support (40% buy rating) but faces substantial financial challenges including persistent losses and negative cash flow from operations. The stock's investment case hinges on successful pipeline development and partnership monetization, though current valuation appears stretched at 37.14x sales given the lack of profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About ProShares UltraShort Bloomberg Natural Gas ETF
KOLD is an inverse leveraged ETF that seeks to provide two times (2x) the inverse daily performance of the Bloomberg Natural Gas Subindex. It is designed for investors looking to profit from falling natural gas prices.
Read more on KOLD →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
